Drug Target Review

SEPTEMBER 25, 2024

Applying our technology has enabled us to develop a new small molecule, TT125-802, and to assign a new role to the epigenetic regulator CBP/p300 as a novel master regulator of non-oncogene resistance. This orally available small molecule binds to the bromodomain of CBP/p300 in a highly specific manner. Bell CC, Gilan O.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

DECEMBER 20, 2020

ALS-4 is a novel small molecule adopting an anti-virulence (non-antibiotic) approach to address the growing unmet medical needs of infections caused by Staphylococcus aureus. Pending Health Canada’s approval, the Phase 1 trial is designed to test the safety, tolerability and pharmacokinetics of ALS-4 in healthy volunteers. About ALS-4.

Small Molecule 40

Small Molecule Clinical Trials Trials Treatment 40

The Pharma Data

JANUARY 5, 2021

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. This is because many proteins do not have small-molecule binding sites. This is not the first deal for RNA therapeutics for Genentech.

RNA 52

RNA Small Molecule DNA Licensing 52

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We have several exciting projects in various stages of discovery, but a small-molecule drug that is causing a lot of excitement at the moment is Capivasertib.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Drug Target Review

NOVEMBER 1, 2023

He previously obtained a PharmD and a MSc degree from Grenoble Alpes University in 2019. Structure–Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode. Andrew McCarthy Andrew is a Team Leader at EMBL Grenoble since 2007. J Med Chem. 2017 Mar 9;60(5):2006–17. J Med Chem.

Clinical Trials 134

Clinical Trials Trials Small Molecule Disease 134

The Pharma Data

SEPTEMBER 29, 2020

The candidate used in the clinical trial was nominated for advancement by Pfizer back in June 2019, which generated a $3m milestone payment at that time. During 2019, Pfizer nominated three distinct clinical candidates from the collaboration with Sosei, two of which have now entered into clinical trials.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Clinical Trials Small Molecule Pharma Companies 52

New Drug Approvals

SEPTEMBER 29, 2024

link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. In the same study, they show that in mice, oral P.

Small Molecule 62

Small Molecule DNA Disease Trials 62

Drug Target Review

MARCH 28, 2024

Between 2000 and 2020, approximately 30 percent of the newly introduced small molecule drugs were derived from natural products. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. References Newman DJ, Cragg GM. Journal of Natural Products. 2020;83(3):770–803. doi:10.1021/acs.jnatprod.9b01285

Production 128

Production Drugs Small Molecule Bioinformatics 128

Molecular Design

DECEMBER 31, 2024

My pulse will be quickenin' With each drop of strychnine We feed to a pigeon It just takes a smidgin To poison a pigeon in the park Tom Lehrer, Poisoning Pigeons in the Park | video ** Ill be reviewing the H2024 study (Occurrence of Natural Selection in Successful Small Molecule Drug Discovery) in this post.

Small Molecule 85

Small Molecule Drugs Production Science 85

The Pharma Data

JANUARY 19, 2021

And in 2019, Caribou co-founder and CRISPR pioneer Jennifer Doudna co-authored a Nature Communications paper describing a system of activating and deactivating single guide RNAs using small-molecule ligands. Most Read Today. Source link.

Research 52

Research RNA Molecular Biology Small Molecule 52

The Pharma Data

NOVEMBER 15, 2020

Urovant’s lead drug candidate, vibegron, is an oral, once-daily small molecule beta-3 agonist being evaluated for the treatment of OAB, abdominal pain associated with irritable bowel syndrome (IBS) in men with OAB, and for men suffering from OAB with benign prostatic hyperplasia (BPH). The condition is most prevalent in men. .

Science 52

Science Small Molecule FDA Approval Therapies 52

The Pharma Data

JANUARY 13, 2021

Structure 3:1031-1039 (1995) 3 Waters J, Biocentury ; October 26, (2018) 4 NCT02273960; ClinicalTrials.gov ; “Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)”; results posted April 1, 2019, updated July 29, 2019 and accessed Jan 11, 2021 5 Ferrant JL et al., International Immunol. (11):1583

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

MARCH 24, 2021

Other COVID-19 initiatives include the research and development of SARS-CoV-2 antibodies that can be combined with BI 767551, small molecules to inhibit its replication, and therapy development to prevent micro coagulation (blood clots). billion EUR (2019: 3.78 billion EUR (2019: 2.72 billion EUR (2019: 3.34

Therapies 52

Therapies Disease Vaccine Small Molecule 52

KIF1A

MAY 27, 2023

After speaking at our 2019 conference and receiving her doctorate, Dr. Lessard joined KIF1A.ORG as its first staff scientist, bringing with her a wealth of expertise in KIF1A, both her own and that of her research colleagues. Dominique Lessard, Chief Science Officer of KIF1A.ORG.

Science 94

Science Small Molecule Disease Research 94

New Drug Approvals

DECEMBER 3, 2022

852808-04-9 ABT-737 is a small molecule drug that inhibits Bcl-2 and Bcl-xL , two members of the Bcl-2 family of evolutionarily-conserved proteins that share B cl-2 H omology (BH) domains. “Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.” ABT-737 Molecular Weight 813.43 PMC 4823827.

Small Molecule 52

Small Molecule Clinical Trials Laboratories Regulations 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for use in individuals 12 years of age and older.

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

NOVEMBER 23, 2020

His most recent position was at Amgen as Director Global Business Development – Transactions, a position he assumed in August 2019 following the acquisition of Nuevolution, a Danish small molecule development company, at which he led the commercial and business activities as Chief Business Officer.

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

The Pharma Data

DECEMBER 10, 2020

LX9211 is a potent, orally delivered, selective small molecule inhibitor of adapter-associated kinase 1 (AAK1). Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

Drug Target Review

MAY 23, 2023

Micro- and macroalgae from both marine and fresh water produce small molecules and secondary metabolites with aggregative, anti-inflammatory, antioxidant, antimicrobial, anti-viral and anti-tumoural bioactivities. Examples include phlorotannins from brown seaweeds and small molecules like terpenoids and peptides, found in microalgae.

Drugs 75

Drugs Small Molecule Production Disease 75

The Pharma Data

NOVEMBER 29, 2020

” “The emergence of the PROTAC technology represents another breakthrough in the identification of small molecule drugs. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment. 2019, 62 , 445?447. ” References: Zhao, Y.;

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

PerkinElmer

JANUARY 4, 2021

Mice with 4T1-luc breast cancer xenografts were treated with a small molecule inhibitor of GLUT1 that blocks glucose transport in cancer models. BiGluc signal production significantly decreased in GLUT1-knockout mice compared to 4T1-luc controls. Reference Maric, T., Mikhaylov, G., Khodakivskyi, P., Bonhoure, N., Yevtodiyenko, A.,

Small Molecule 52

Small Molecule Production Laboratories Disease 52

The Pharma Data

AUGUST 18, 2020

Small molecule discovery. The drug repositioning pillar builds on Johnson & Johnson’s ongoing partnership with the prestigious Rega Institute at KU Leuven in Belgium, where a team of scientists are screening molecule libraries containing thousands of existing compounds to determine if they have potential as COVID-19 treatments.

Treatment 52

Treatment Pharmaceutical Companies Research Small Molecule 52

New Drug Approvals

DECEMBER 16, 2023

April 2019). “Small-molecule factor B inhibitor for the treatment of complement-mediated diseases” Proceedings of the National Academy of Sciences of the United States of America. Archived from the original on 12 December 2023. Retrieved 6 September 2023. 116 (16): 7926–7931.

FDA 62

FDA Small Molecule FDA Approval Treatment 62

The Pharma Data

FEBRUARY 25, 2022

About ABRILADA (adalimumab-afzb) ABRILADA is a citrate-free biosimilar to Humira that received FDA approval in 2019 for the treatment of certain patients with RA, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis.

Biosimilars 52

Biosimilars FDA FDA Approval Small Molecule 52

The Pharma Data

NOVEMBER 4, 2020

million as of December 31, 2019. million for the same period in 2019. million for the same period in 2019. per share, for the quarter ended September 30, 2019. 2019. 2019. December 31, 2019. December 31, 2019.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Treatment 52

The Pharma Data

JULY 2, 2023

To this end, the team carefully evaluated hits from a screen of around ten thousand small molecule compounds and identified icFSP1 as a new in vivo effective drug. Although FSP1 has been considered as an attractive drug target for cancer therapy, in vivo efficacious FSP1 inhibitors have been lacking.

Therapies 40

Therapies Small Molecule Pharmacokinetics Disease 40

Metabolite Tales Blog

MAY 12, 2023

In 2022, fewer of the 19 newly FDA approved small molecule drugs contained F atoms (adagrasib, lenacapavir, oteseconazole, vonoprazan), but this was followed by 3 more approvals of F-containing drugs in the first quarter of 2023 alone (pirtobrutinib, omaveloxolone, leniolisib). Angew Chem Int Ed Engl. ACS Med Chem Lett.

Drugs 52

Drugs Small Molecule FDA Approval Metabolic Stability 52

The Pharma Data

JANUARY 18, 2021

Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT).

Small Molecule 52

Small Molecule Hospitals Treatment Clinical Trials 52

Drug Target Review

JULY 12, 2023

Once a new drug target is identified, a proprietary deep learning artificial intelligence (AI) platform we call Fluency can rapidly identify small molecules that selectively bind to a target of interest. Author Bio: Brett Hall Brett has been Chief Scientific Officer at Immuneering since November 2019.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

The Premier Consulting Blog

AUGUST 8, 2024

October 2019. [iv] Typically, new drug development under the 505(b)(2) pathway requires less capital and time and has a higher success rate versus the 505(b)(1) pathway, where the Sponsor develops safety and effectiveness information from scratch. July 28, 2023. iii] US Food and Drug Administration. Guidance for Industry. Website: [link].

Drugs 52

Drugs Pharmacokinetics FDA Production 52

The Pharma Data

JANUARY 19, 2021

Syros is redefining the power of small molecules to control the expression of genes. About Syros Pharmaceuticals. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches.

Small Molecule 52

Small Molecule Clinical Trials Pharmaceuticals Virus 52

The Pharma Data

JANUARY 17, 2021

As Crooke explained, “With small molecules, if you make any chemical change, you have a new ballgame. I spent 2019 discussing this approach with the FDA,” Crooke recalled. “I’m still involved with the science that we created and continue to advance,” he told BioSpace. That’s not the case with RNA-targeted drugs.

Disease 52

Disease Clinical Trials Small Molecule Treatment 52

The Pharma Data

MAY 6, 2022

The booster schedule is based on the labeling information of the vaccine used for the primary series EUA Statement Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 5 years of age and older.

FDA Approval 52

FDA Approval Licensing Licensing FDA 52

The Pharma Data

FEBRUARY 24, 2022

The booster schedule is based on the labeling information of the vaccine used for the primary series EUA Statement Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 5 years of age and older.

Vaccine 52

Vaccine FDA Small Molecule Immune Response 52

The Pharma Data

DECEMBER 12, 2020

AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. Alexion achieved impressive revenue growth over the last few years, with revenues of $5.0bn in 2019 (21% year-on-year growth).

Regulations 75

Regulations International Disease Small Molecule 75

LifeSciVC

APRIL 27, 2023

Fourteen years on, this corporate experiment has gone far beyond the initial idea, and has established an R&D engine more effective than most big pharma R&D groups at producing best-in-class small molecules against targets that matter in human disease biology. Our long-time clinical development lead, Bhaskar Srivastava, an M.D.

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40

The Pharma Data

NOVEMBER 8, 2021

“HER-MES is the first study that directly compared the therapeutic effects of an antibody and a small molecule in migraine prevention,” said Uwe Reuter, M.D., 5,17 The 2019 Global Burden of Disease Study ranks migraine among the top 10 causes of years lived with disability worldwide.18 versus 38.9%).

Therapies 52

Therapies FDA Approval Treatment Small Molecule 52